VeriMomSollte ich naproxen in der Schwangerschaft meiden? | VeriMom
Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
ECHA regulatory hazard statements
- •H361
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- Ist naproxen in der Schwangerschaft sicher?
- Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
- Ist naproxen während des Stillens sicher?
- Naproxen is excreted into breast milk in low amounts but has a long half‑life and case reports of infant effects; professional guidance (LactMed, NHS Specialist Pharmacy Service, MotherToBaby) recommends caution and short‑term use if needed and consideration of alternative NSAIDs with shorter half‑lives. Mechanism is passive transfer into milk consistent with systemic exposure; expected exposure from topical cosmetic use is low but measurable.
- Ist naproxen sicher für Babyhaut?
- No infant‑specific dermal teratogenicity data were found; systemic hazard stems from naproxen’s known reproductive effects. For baby (0–3 yr) skin, exposure scoring is increased by +1 due to immature barrier and higher surface‑area‑to‑weight, so exposure is moderate if a naproxen‑containing topical product were used repeatedly. There is no evidence to raise hazard or mechanism above the adult systemic evidence without infant‑specific studies.
- Wie bewertet VeriMom naproxen?
- VeriMom bewertet naproxen mit 20/100 (hohes Risiko) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu naproxen?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu naproxen basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.